CustomFlex artificial iris receives transitional pass-through payment status

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The CustomFlex artificial iris was granted transitional pass-through payment status from CMS, effective Jan. 1, 2020.

The artificial iris from VEO Ophthalmics was approved by the FDA in May 2018 and is the only iris prosthesis available in the United States for use in children and adults for the treatment of iris defects resulting from congenital aniridia, acquired defects, or conditions associated with completely or partially missing or damaged irises.

The HCPCS code for the device is C1839 (Iris prosthesis).

“Since receiving FDA approval, the CustomFlex artificial iris has helped many patients suffering from symptomatic aniridia,” Ron Gilliland, president and CEO of VEO Ophthalmics, said in a press release. “The decision by CMS to grant pass-through payment status will now make this unique technology available to more patients in the U.S.”